United States Charles Tender

Charles River Laboratories International Inc. is proud to host the 3rd Annual World Congress Delivering Therapies to the Clinic Faster on September 23-24 2019 in Cambridge Mass. This years World Congresswill explore novel approaches to drug development that effectively reduce program timelines and accelerate delivery to the clinic. The World Congressis a two-day scientific program that will illustrate methods to successfully cut time to market and highlight how next generation technologies like artificial intelligence and genomics are expediting target discovery and drug development.Featured speakers includeTimothy Yu M.D. Ph.D. Attending Physician Division of Genetics and Genomics at Boston Childrens Hospital Associate Member of the Broad Institute and Assistant Professor in Pediatrics at Harvard Medical School will discuss the accelerated development of milasen as an example of truly individualized genomic medicine.Allyson Berent DVM DACVIM Chief Operating Officer of GeneTx Biotherapeutics and Chief Science Officer of the Foundation for Angelman Syndrome Therapeutics will share her personal journey from veterinary specialist to CSO of a non-profit and co-founder of a biotherapeutic company when her infant daughter was diagnosed with a random rare neurogenetic disorder called Angelman syndrome.On September 23 2019 the World Congress will host a panel to discuss how artificial intelligence AI can be applied in drug discovery. Moderated by Carey Goldberg Editor of WBURs CommonHealth panelists include Liam Loscalzo of nFerence and David Clark of Charles River among others. The panel will explore how the industry can quantify the impact of AI on drug discovery what the real world applications of AI may be and how the field may advance. Tuesdays panel discussion will focus on the use of genomics data and will be moderated by Martin Mackay Ph.D. co-founder of Rallybio and member of Charles Rivers Board of Directors.Charles River Annual Research AwardThis year Matt Wilsey Chairman President Co-founder of the Grace Science Foundation will receive the Charles River Annual Research Award on behalf of the Grace Science Foundation and its search for a cure for NGLY1 deficiency. The Grace Science team hopes that their Silicon Valley approach with flat structure nimbleness and frugality as key tenets can be applied to both rare and more prevalent diseases for faster less expensive and more comprehensive disease understanding and treatment. Previous winners of the Annual Research Award include Sonia Vallabah and Eric Minkel researchers with the Broad Institute of MIT and Harvard and co-founders of the Prion Alliance and David Hysong Patient Founder Chief Executive Officer of Shepherd Therapeutics.